Omeros Corp OMER
Omeros Corp (Nasdaq: OMER) is a hematology drug developer. Its lead program, YARTEMLEA (narsoplimab-wuug), is in Phase 1 for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). Its next catalyst on record is YARTEMLEA: Enrollment to begin in two investigator-sponsored studies (hyperinflammatory ARDS; prophylactic pediatric TA-TMA) (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: YARTEMLEA — Enrollment to begin in two investigator-sponsored studies (hyperinflammatory ARDS; prophylactic pediatric TA-TMA) (2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| YARTEMLEA (narsoplimab-wuug) | TA-TMA in adults and children aged 2 and older | antibody | Approved |
| OMS1029 | long-acting MASP-2 antibody; Phase 2 indication being selected | antibody | Phase 1 |
| OMS527 (PDE7 inhibitor) | cocaine use disorder | small molecule | Phase 1 |
| MASP-2 oral small molecule | — | small molecule | Pre-clinical |
| OncotoX-AML (OMS805) | acute myeloid leukemia | biologic-other | Pre-clinical |
| T-CAT platform | bacterial, fungal, viral and parasitic infections | antibody | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 hematology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.